NCT04984590 is a clinical trial of IOPCL AMD MAG in Low Vision, sponsored by OnPoint Vision Inc.

Who is sponsoring NCT04984590?

NCT04984590 is sponsored by OnPoint Vision Inc.

What drugs are being tested in NCT04984590?

Interventions in NCT04984590: IOPCL AMD MAG.

What condition does NCT04984590 study?

NCT04984590 studies Low Vision, Age Related Macular Degeneration.

Is NCT04984590 still recruiting?

NCT04984590 is currently completed. Last updated 31 January 2025.

Are results published for NCT04984590?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-31 · How we verify

NCT04984590

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects

Completed Results posted Last updated 31 January 2025

What this trial tests

trial testing IOPCL AMD MAG in Low Vision in 9 participants. Completed in 20 March 2024.

Timeline

21 January 2022

Primary endpoint
20 March 2024

20 March 2024

Quick facts

Lead sponsor	OnPoint Vision Inc
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	21 January 2022
Primary completion	20 March 2024
Estimated completion	20 March 2024
Sites	1 location across United States

Drugs / interventions tested

IOPCL AMD MAG

Conditions studied

Low Vision — all drugs for Low Vision →
Age Related Macular Degeneration — all drugs for Age Related Macular Degeneration →

Sponsor

OnPoint Vision Inc

Who can join

55 and older, any sex, with Low Vision or Age Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Tilt of the PCIOL and IOPCL MAG Complex Primary · 12 Months

Measuring postoperative tilt of the PCIOL and IOPCL MAG complex. Tilt was defined as less than or equal to 10 degrees.

PCIOL Tilt <= 10 degrees

Group	Value	95% CI
IOPCL AMD MAG	9

IOPCL MAG Tilt <=10 degrees

Group	Value	95% CI
IOPCL AMD MAG	9

IOPCL MAG Decentration Primary · 12 Months

Measures the decentration of the IOPCL MAG against the PCIOL. Decentration was defined as the horizontal and vertical distances greater than or equal to 0.25mm or less than or equal to 0.75mm.

Number of eyes with IOPCL MAG horizontal and vertical distances >= 0.25mm and <=0.75mm

Group	Value	95% CI
IOPCL AMD MAG	9

Number of eyes with IOPCL MAG horizontal and vertical distances < 0.25mm and >0.75mm

Group	Value	95% CI
IOPCL AMD MAG	0

Uncorrected Near Visual Acuity at 14cm Change From Baseline (Letters) (≥ 75% Achieving ≥ 10 Letters) Primary · 12 Months

Proportion of eyes (≥ 75%) able to achieve improvement of 10 letters or more of uncorrected near visual acuity (at 14 cm) at 12 months from baseline

Gain of >= 20 letters (>= 4 lines)

Group	Value	95% CI
IOPCL AMD MAG	8

Gain of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	9

Gain of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	9

Gain of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	9

No change

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >=10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 15 letters (>=3 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Uncorrected Near Visual Acuity at 14cm Change From Baseline (Letters) (≥ 50% Achieving ≥ 20 Letters) Secondary · 12 months

Proportion of eyes (≥ 50%) able to achieve improvement of 20 letters or more of uncorrected near visual acuity (at 14 cm) at 12 months from baseline

Gain of >= 20 letters (>= 4 lines)

Group	Value	95% CI
IOPCL AMD MAG	8

Gain of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	9

Gain of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	9

Gain of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	9

No change

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Postoperative Uncorrected Near Visual Acuity at 14cm Compared to Preoperative Best Corrected Near Visual Acuity at 30cm With +3.0D Add (≥ 75% Achieving ≥ 10 Letters) Secondary · 12 months

Proportion of eyes (≥ 75%) able to achieve improvement of 10 letters or more when comparing uncorrected near visual acuity (UCNVA) (at 14 cm) at 12 months from baseline BCNVA (at 30 cm, wearing the appropriate preoperative distance refractive correction in addition to +3.0D add)

Gain of >= 20 letters (>= 4 lines)

Group	Value	95% CI
IOPCL AMD MAG	5

Gain of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	8

Gain of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	9

Gain of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	9

No change

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Postoperative Uncorrected Near Visual Acuity at 14cm Compared to Preoperative Best Corrected Near Visual Acuity at 30cm With +3.0D Add (≥ 50% Achieving ≥ 20 Letters) Secondary · 12 months

Proportion of eyes (≥ 50%) able to achieve improvement of 20 letters or more when comparing uncorrected near visual acuity (UCNVA) (at 14 cm) at 12 months from baseline BCNVA (at 30 cm, wearing the appropriate preoperative distance refractive correction in addition to +3.0D add)

Gain of >= 20 letters (>= 4 lines)

Group	Value	95% CI
IOPCL AMD MAG	5

Gain of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	8

Gain of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	9

Gain of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	9

No change

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Postoperative Best Corrected Near Visual Acuity at 14cm Compared to Preoperative Best Corrected Near Visual Acuity at 30cm With +3.0D Add (≥ 75% Achieving ≥ 10 Letters) Secondary · 12 months

Proportion of eyes (≥ 75%) able to achieve improvement of 10 letters or more when comparing best corrected near visual acuity (BCNVA) (at 14 cm) at 12 months from baseline BCNVA (at 30 cm, wearing the appropriate preoperative distance refractive correction in addition to +3.0D add)

Gain of >= 20 letters (>= 4 lines)

Group	Value	95% CI
IOPCL AMD MAG	5

Gain of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	8

Gain of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	9

Gain of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	9

No change

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Postoperative Best Corrected Near Visual Acuity at 14cm Compared to Preoperative Best Corrected Near Visual Acuity at 30cm With +3.0D Add (≥ 50% Achieving ≥ 20 Letters) Secondary · 12 months

Proportion of eyes (≥ 50%) able to achieve improvement of 20 letters or more when comparing best corrected near visual acuity (BCNVA) (at 14 cm) at 12 months from baseline BCNVA (at 30 cm, wearing the appropriate preoperative distance refractive correction in addition to +3.0D add)

Gain of >= 20 letters (>= 4 lines)

Group	Value	95% CI
IOPCL AMD MAG	5

Gain of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	8

Gain of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	9

Gain of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	9

No change

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 5 letters (>= 1 line)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 10 letters (>= 2 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Loss of >= 15 letters (>= 3 lines)

Group	Value	95% CI
IOPCL AMD MAG	0

Adverse events — posted to ClinicalTrials.gov

Time frame: 12 Months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

IOPCL AMD MAG

Serious: 0/9 (0%)

Deaths: 0/9

Other adverse events (1 terms — click to expand)

Reaction	System	IOPCL AMD MAG
Bilateral pruritis	Eye disorders	—

Data from ClinicalTrials.gov NCT04984590 adverse events section.

Sponsor's own description

This early feasibility study aims to improve near vision in subjects 55 years or older who have a clinical diagnosis of Age-Related Macular Degeneration. Subjects must have previously been implanted with either the Alcon Model SN60WF or Model SA60AT intraocular lens at least 6-months prior to receiving the IOPCL (intraocular pseudophakic capsular lens). Subject will be followed for a period of 12-months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Low Vision

Currently open trials in the same condition.

NCT06914076 — Evaluating The Effectiveness Of Structured Psychosocial Counseling On Mental Health And FI Individuals With Low Vision · NA · active not recruiting
NCT07218991 — Wearable Echolocation Aids Using Parametric Sound · NA · recruiting
NCT06107881 — Beacon Sensors and Telerehabilitation to Assess and Improve Use of Devices (BeST-AID) for Low Vision · NA · recruiting
NCT05888441 — Obstacle Negotiation in Older People With and Without Vision Impairment · NA · recruiting

Other OnPoint Vision Inc trials

Trials by the same sponsor.

NCT05113979 — Early Feasibility Study to Evaluate the AccuraSee in Correcting Residual Refractive Errors After Cataract Surgery · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04984590 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OnPoint Vision Inc
Last refreshed: 31 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04984590.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04984590

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Low Vision

Other OnPoint Vision Inc trials

Verify against primary sources